Lorenzin: “At the EMA they told me that testing drugs on women costs too much”

“Until recently, gender medicine seemed reserved for professionals and not for society, when I talked about it to EMA they told me ‘it costs too much to test drugs on women too’, and this speaks volumes about the idea that has the topic at the highest level, they were resistances that fortunately we have started to break down today. ”Thus the Honorable Beatrice Lorenzin, member of the Budget Committee of the Chamber of Deputies, spoke in the webinar“ Women at 360 °. The challenge of Medicine of Gender for chronic autoimmune rheumatological and dermatological diseases “, promoted by Ucb Italia.” Gender medicine has been sanctioned by the law decree that bears my name and in the future it must be part of all policies – explained Lorenzin -. Covid was a prime example of how medicine must be adapted to gender because diseases can have different effects on men and women. “” For example, on biological drugs for cancer we already have a lot of data and a gender specificity has been established with respect to certain pathologies – added the former Minister of Health – all specialized medicine is tested on single DNA but also on gender, and on this we cannot back down despite debatable arguments such as high costs on drug trials on women “.